Arjo AB (publ)
Arjo AB (publ) develops and sells medical devices and solutions for patients for clinical and financial outcomes for healthcare in Europe, Asia, Latin America, Africa, and Pacific. It offers products and solutions for patient handling, hygiene, disinfection, medical beds, pressure injury prevention, diagnostics, prevention of deep vein thrombosis and treatment of edema, leg ulcer treatment and pr… Read more
Arjo AB (publ) (ARRJF) - Net Assets
Latest net assets as of December 2025: $7.46 Billion USD
Based on the latest financial reports, Arjo AB (publ) (ARRJF) has net assets worth $7.46 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($14.98 Billion) and total liabilities ($7.52 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.46 Billion |
| % of Total Assets | 49.79% |
| Annual Growth Rate | -1.82% |
| 5-Year Change | 8.31% |
| 10-Year Change | -30.03% |
| Growth Volatility | 18.13 |
Arjo AB (publ) - Net Assets Trend (2013–2025)
This chart illustrates how Arjo AB (publ)'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Arjo AB (publ) (2013–2025)
The table below shows the annual net assets of Arjo AB (publ) from 2013 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $7.46 Billion | -10.57% |
| 2024-12-31 | $8.34 Billion | +9.97% |
| 2023-12-31 | $7.58 Billion | -0.55% |
| 2022-12-31 | $7.62 Billion | +10.73% |
| 2021-12-31 | $6.88 Billion | +22.29% |
| 2020-12-31 | $5.63 Billion | -4.80% |
| 2019-12-31 | $5.91 Billion | +8.97% |
| 2018-12-31 | $5.43 Billion | +6.96% |
| 2017-12-31 | $5.07 Billion | -52.39% |
| 2016-12-31 | $10.66 Billion | +4.21% |
| 2015-12-31 | $10.23 Billion | -3.54% |
| 2014-12-31 | $10.60 Billion | +14.05% |
| 2013-12-31 | $9.30 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Arjo AB (publ)'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 29.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $6.53 Billion | 87.62% |
| Common Stock | $91.00 Million | 1.22% |
| Other Components | $832.00 Million | 11.16% |
| Total Equity | $7.46 Billion | 100.00% |
Arjo AB (publ) Competitors by Market Cap
The table below lists competitors of Arjo AB (publ) ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mcmillan Shakespeare Ltd
AU:MMS
|
$491.30 Million |
|
Vgi Partners Global Investments Ltd
AU:VG1
|
$491.32 Million |
|
Mutares SE & Co. KGaA
XETRA:MUX
|
$491.41 Million |
|
Ingram Micro Holding Corporation
NYSE:INGM
|
$491.62 Million |
|
Maitri Health Technologies Corp
PINK:MHTCF
|
$491.23 Million |
|
JLGRF
PINK:JLGRF
|
$491.18 Million |
|
PayPoint plc
OTCGREY:PYPTF
|
$490.59 Million |
|
Dril-Quip Inc
F:DQU
|
$490.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Arjo AB (publ)'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 8,338,000,000 to 7,457,000,000, a change of -881,000,000 (-10.6%).
- Net income of 334,000,000 contributed positively to equity growth.
- Dividend payments of 259,000,000 reduced retained earnings.
- Other comprehensive income decreased equity by 1,807,000,000.
- Other factors increased equity by 851,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $334.00 Million | +4.48% |
| Dividends Paid | $259.00 Million | -3.47% |
| Other Comprehensive Income | $-1.81 Billion | -24.23% |
| Other Changes | $851.00 Million | +11.41% |
| Total Change | $- | -10.57% |
Book Value vs Market Value Analysis
This analysis compares Arjo AB (publ)'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.11x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $41.72 | $3.07 | x |
| 2015-12-31 | $40.24 | $3.07 | x |
| 2016-12-31 | $39.13 | $3.07 | x |
| 2017-12-31 | $18.63 | $3.07 | x |
| 2018-12-31 | $19.93 | $3.07 | x |
| 2019-12-31 | $21.71 | $3.07 | x |
| 2020-12-31 | $20.67 | $3.07 | x |
| 2021-12-31 | $25.28 | $3.07 | x |
| 2022-12-31 | $27.99 | $3.07 | x |
| 2023-12-31 | $27.84 | $3.07 | x |
| 2024-12-31 | $30.61 | $3.07 | x |
| 2025-12-31 | $27.38 | $3.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Arjo AB (publ) utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.04%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 2.01x
- Recent ROE (4.48%) is below the historical average (5.90%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 5.84% | 8.18% | 0.51x | 1.40x | $-441.20 Million |
| 2015 | 3.00% | 3.78% | 0.58x | 1.37x | $-715.70 Million |
| 2016 | 4.60% | 6.28% | 0.53x | 1.38x | $-575.80 Million |
| 2017 | 2.33% | 1.53% | 0.63x | 2.41x | $-389.40 Million |
| 2018 | 5.45% | 3.60% | 0.63x | 2.42x | $-246.70 Million |
| 2019 | 6.81% | 4.52% | 0.62x | 2.44x | $-188.40 Million |
| 2020 | 9.34% | 5.79% | 0.66x | 2.46x | $-37.00 Million |
| 2021 | 10.78% | 8.18% | 0.62x | 2.12x | $53.50 Million |
| 2022 | 5.89% | 4.50% | 0.62x | 2.12x | $-313.40 Million |
| 2023 | 6.33% | 4.37% | 0.71x | 2.04x | $-278.20 Million |
| 2024 | 5.97% | 4.41% | 0.69x | 1.95x | $-335.80 Million |
| 2025 | 4.48% | 3.04% | 0.73x | 2.01x | $-411.70 Million |
Industry Comparison
This section compares Arjo AB (publ)'s net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $629,037,105
- Average return on equity (ROE) among peers: -5.26%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Arjo AB (publ) (ARRJF) | $7.46 Billion | 5.84% | 1.01x | $491.29 Million |
| Accendra Health Inc (ACH) | $314.40 Million | 8.91% | 1.75x | $22.90K |
| Cardinal Health Inc (CAH) | $255.60 Million | 13.15% | 1.57x | $50.81 Billion |
| Cencora Inc. (COR) | $4.01 Billion | 11.02% | 2.01x | $62.31 Billion |
| Cosmos Health Inc. (COSM) | $36.04 Million | -51.45% | 0.83x | $8.90 Million |
| EDAP TMS SA (EDAP) | $50.05 Million | 1.40% | 0.54x | $115.72 Million |
| Empro Group Inc. Ordinary shares (EMPG) | $741.21K | -42.90% | 4.10x | $9.16 Million |
| Energy Management International Inc (ENMI) | $-362.21K | 0.00% | 0.00x | $383.13K |
| Exlites Holdings International Inc (EXHI) | $-84.27 | 0.00% | 0.00x | $574.58K |
| Galenica AG (GALNF) | $999.54 Million | 12.50% | 1.21x | $3.75 Billion |